UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Revisiting the role of interleukin-8 in chronic lymphocytic leukemia

Scientific reports, 2017-11, Vol.7 (1), p.15714-8, Article 15714

2017

Volltextzugriff (PDF)

miRNome profiling of LSC-enriched CD34 + CD38 - CD26 + fraction in Ph + CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool

Frontiers in pharmacology, 2021-01, Vol.11, p.612573-612573

2021

Volltextzugriff (PDF)

Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells

Haematologica (Roma), 2017-07, Vol.102 (7), p.e257

2017

Volltextzugriff (PDF)

CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia

Haematologica (Roma), 2010-05, Vol.95 (5), p.768-775

2010

Volltextzugriff (PDF)

Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and clinical studies

European journal of haematology, 2008-08, Vol.81 (2), p.94-99

2008

Volltextzugriff (PDF)

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Journal of hematology and oncology, 2023-04, Vol.16 (1), p.43-43, Article 43

2023

Volltextzugriff (PDF)

SHIP‐1 protein level and phosphorylation status differs between CLL cells segregated by ZAP‐70 expression

British journal of haematology, 2008-01, Vol.140 (1), p.117-119

2008

Volltextzugriff (PDF)

Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia

Biochemical pharmacology, 2008-02, Vol.75 (4), p.857-865

2008

Volltextzugriff (PDF)

Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway

International immunopharmacology, 2006-05, Vol.6 (5), p.715-723

2006

Volltextzugriff (PDF)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy

Frontiers in immunology, 2023-09, Vol.14, p.1241600-1241600

2023

Volltextzugriff (PDF)

In vitro susceptibility of CD4 + and CD8 + T cell subsets to fludarabine

Biochemical pharmacology, 2003-12, Vol.66 (11), p.2185-2191

2003

Volltextzugriff (PDF)

P041: Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status

HemaSphere, 2022-10, Vol.6 (Suppl), p.19-19

2022

Volltextzugriff (PDF)

More Than 4 Cycles of ABVD for the Treatment of Stage I–II Hodgkin's Lymphoma?

Blood, 2005-11, Vol.106 (11), p.4719-4719

2005

Volltextzugriff (PDF)

Erythrocytapheresis with Recombinant Human Erythropoietin in Hereditary Hemochromatosis Therapy: A New Alternative

Vox sanguinis, 2000-01, Vol.79 (1), p.40-45

2000

Volltextzugriff (PDF)

Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Have Prognostic Impact on Survival in Nodal Non-Hodgkin T-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.11936-11937

2022

Volltextzugriff (PDF)

Low Percentage of Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Is Associated with Inferior Overall Survival in Diffuse Large B Cell Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.2415-2415

2021

Volltextzugriff (PDF)

Treatment of hematologic neoplasms during pregnancy

Medicina (Buenos Aires), 2007, Vol.67 (6 Pt 2), p.729

2007

Volltextzugriff (PDF)

The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia

Haematologica (Roma), 2006-04, Vol.91 (4), p.574

2006

Volltextzugriff (PDF)

Bone Marrow Microenvironment Immune Cells Measured By Flow Cytometry Can Predict Survival and Identify a Subgroup in Risk of Early Relapse in Diffuse Large B Cell Lymphoma Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.23-23

2020

Volltextzugriff (PDF)

Induction Treatment and Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation in Young Patients (<65 years) with High-Risk Cytogenetic and Secondary Acute Myeloid Leukemia (AML): A Single Center Experience in Argentina with CLAG-M and 7+3

Blood, 2019-11, Vol.134 (Supplement_1), p.5132-5132

2019

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(83)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(36)
Humans
(33)
Female
(15)
Male
(15)
Hematology
(11)
Adult
(10)
Biological And Medical Sciences
(9)
Covid-19
(9)
Middle Aged
(9)
Medical Sciences
(8)
Aged
(7)
Medicine, General & Internal
(7)
Oncology
(6)
General & Internal Medicine
(5)
Leukemia, Lymphocytic, Chronic, B-Cell - Pathology
(5)
Pharmacology & Pharmacy
(5)
Severe Acute Respiratory Syndrome Coronavirus 2
(5)
Aged, 80 And Over
(4)
Animals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Revisiting the role of interleukin-8 in chronic lymphocytic leukemia

miRNome profiling of LSC-enriched CD34 + CD38 - CD26 + fraction in Ph + CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool

Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells

CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia

Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and clinical studies

Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

SHIP‐1 protein level and phosphorylation status differs between CLL cells segregated by ZAP‐70 expression

Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia

Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy

In vitro susceptibility of CD4 + and CD8 + T cell subsets to fludarabine

P041: Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status

More Than 4 Cycles of ABVD for the Treatment of Stage I–II Hodgkin's Lymphoma?

Erythrocytapheresis with Recombinant Human Erythropoietin in Hereditary Hemochromatosis Therapy: A New Alternative

Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Have Prognostic Impact on Survival in Nodal Non-Hodgkin T-Cell Lymphoma

Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Low Percentage of Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Is Associated with Inferior Overall Survival in Diffuse Large B Cell Lymphoma

Treatment of hematologic neoplasms during pregnancy

Ruxolitinib In Myelofibrosis (MF) Patients Through Compassionate Use Program (CUP). Argentinian Experience

The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia

Bone Marrow Microenvironment Immune Cells Measured By Flow Cytometry Can Predict Survival and Identify a Subgroup in Risk of Early Relapse in Diffuse Large B Cell Lymphoma Patients

In Pursuit of Surrogate Markers for Treatment-Free Remission in Patients with Chronic Myeloid Leukemia from Argentina Stop Trial

High Level of Successful TKI Discontinuation in Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of AST-Argentina Stop Trial

Induction Treatment and Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation in Young Patients (<65 years) with High-Risk Cytogenetic and Secondary Acute Myeloid Leukemia (AML): A Single Center Experience in Argentina with CLAG-M and 7+3

Suchergebnisse filtern